Featured Research

from universities, journals, and other organizations

Surprise finding reveals how adaptive our immune systems can be

Date:
July 15, 2013
Source:
Garvan Institute of Medical Research
Summary:
Studies of patients with immunodeficiencies involving single gene mutations can reveal a great deal about our immune systems, especially when actual symptoms do not accord with clinical expectations. Australian scientists acknowledge such a gap between expectation and reality in a new study, which examines people with "Autosomal Dominant Hyper IgE Syndrome."

Studies of patients with immunodeficiencies involving single gene mutations can reveal a great deal about our immune systems, especially when actual symptoms do not accord with clinical expectations.

Australian scientists acknowledge such a gap between expectation and reality in a new study, which examines people with 'Autosomal Dominant Hyper IgE Syndrome'.

Hyper IgE Syndrome arises from a mutation in the STAT3 gene. This makes patients slightly more susceptible than normal to blood cancers known as 'lymphomas', and exposes them to recurrent skin infections and pneumonia. While these symptoms are certainly a problem, laboratory experiments and animal models predict far more susceptibility to viruses and cancers than is actually the case.

PhD student Megan Ives, Dr Elissa Deenick and Associate Professor Stuart Tangye, from Sydney's Garvan Institute of Medical Research, discovered that the immune systems of people with Hyper IgE Syndrome have much more redundancy, or compensatory capacity, than expected. Specifically, the research team expected patients to be significantly less able to create effective 'killer T cells', the class of immune cells that destroy invading microbes and cancers. Their results are published in the Journal of Allergy and Clinical Immunology, now online.

"Under normal circumstances, the STAT3 molecule passes biochemical signals in T cells which instruct them to turn on their killing machinery. In Hyper IgE patients, who lack the gene, the signal just appears to take a diversion most of the time, and that seems to work," said Dr Elissa Deenick.

"There are certain molecules that Killer T cells need in order to become effective -- and possibly in the case of a very few viruses and lymphomas, Hyper IgE patients are unable to generate the signals necessary to make these molecules. However they do make effective responses against most viruses and cancers."

Associate Professor Stuart Tangye believes the study is important because it underlines the differences between results obtained through mouse model work and real human infectious diseases. "I believe it's just as useful to find an explanation for a prediction that didn't happen as it is to have a prediction confirmed," he said.

"Megan's work allows us to understand why Hyper IgE patients are not super unwell, as you would expect. That understanding is vital clinically, because it may allow us to address the actual symptoms more effectively."


Story Source:

The above story is based on materials provided by Garvan Institute of Medical Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Megan L. Ives, Cindy S. Ma, Umaimainthan Palendira, Anna Chan, Jacinta Bustamante, Stephanie Boisson-Dupuis, Peter D. Arkwright, Dan Engelhard, Diana Averbuch, Klaus Magdorf, Joachim Roesler, Jane Peake, Melanie Wong, Stephen Adelstein, Sharon Choo, Joanne M. Smart, Martyn A. French, David A. Fulcher, Matthew C. Cook, Capucine Picard, Anne Durandy, Miyuki Tsumura, Masao Kobayashi, Gulbu Uzel, Jean-Laurent Casanova, Stuart G. Tangye, Elissa K. Deenick. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8 T-cell memory formation and function. Journal of Allergy and Clinical Immunology, 2013; DOI: 10.1016/j.jaci.2013.05.029

Cite This Page:

Garvan Institute of Medical Research. "Surprise finding reveals how adaptive our immune systems can be." ScienceDaily. ScienceDaily, 15 July 2013. <www.sciencedaily.com/releases/2013/07/130715091226.htm>.
Garvan Institute of Medical Research. (2013, July 15). Surprise finding reveals how adaptive our immune systems can be. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/07/130715091226.htm
Garvan Institute of Medical Research. "Surprise finding reveals how adaptive our immune systems can be." ScienceDaily. www.sciencedaily.com/releases/2013/07/130715091226.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins